McKesson stock highlights oncology push and Q1 growth at Wells Fargo conference

Published on 09/08/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock is drawing investor attention as the company combines strong first-quarter fiscal 2027 growth with a USD 2.25 billion Precision Medicine Group acquisition and continued capital returns, underlined at the Wells Fargo healthcare conference on September 8, 2026.

Mitarbeiter sortieren unbeschriftete Pakete in einem großen Pharma-Logistiklager mit Regalen — Fotorealistisches Bild zeigt McKesson Corporation ISIN US58155Q1031 als Pharmagroßhändler in modernem Distributionslager mit vielen Mitarbeitern, Illustration mit AI erstellt.

McKesson Corporation stock (ISIN US58155Q1031) is in focus after management used the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026 to underline strong first-quarter fiscal 2027 growth and a USD 2.25 billion acquisition of Precision Medicine Group that deepens its oncology and biopharma services footprint.Investing.com For investors, the mix of higher-growth specialty segments and disciplined shareholder returns has become a key part of the equity story.

Conference message: growth, M&A and shareholder returns

At the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, McKesson emphasized that its latest quarter showed broad strength across the business, led by the North America Pharmaceutical Distribution segment and specialty services.Investing.com Management highlighted that the USD 2.25 billion Precision Medicine Group deal is part of a multi-year strategy to build on its core distribution franchise while expanding higher-growth, higher-value services in oncology and biopharma.Investing.com

According to the conference summary, revenue in North America Pharmaceutical Distribution grew about 5 percent in the first quarter of fiscal 2027, while adjusted operating profit in the segment rose roughly 19 percent in the same period, underscoring the operating leverage in McKesson’s core distribution business.Investing.com In Oncology and Multi-Specialty, first-quarter revenue increased approximately 33 percent, with adjusted operating profit up around 41 percent year over year, highlighting how the oncology pivot is already contributing to earnings momentum.Investing.com

Segment performance and quantified comparisons

Beyond distribution and oncology, McKesson’s Prescription Technology Solutions segment reported first-quarter fiscal 2027 revenue growth of 9 percent and adjusted operating profit growth of 13 percent, which sits at the high end of its long-term adjusted operating profit growth target of 10 to 13 percent.MarketBeat This puts the segment’s current performance slightly above the midpoint of management’s multi-year ambitions, suggesting that technology-driven access and affordability programs across therapeutic categories are scaling as planned.

In the Medical-Surgical business, first-quarter revenue rose roughly 4 percent, while adjusted operating profit declined about 20 percent, partly due to one-time administrative costs.MarketBeat McKesson reiterated its expectation for full-year adjusted operating profit growth of 0 to 4 percent in this segment, signalling that management views the current margin pressure as temporary and supported by new business wins, private-label expansion and cost initiatives over the remainder of the fiscal year.MarketBeat

Capital allocation and dividend growth

Capital allocation remains a central pillar of the McKesson investment case. The company indicated that it expects to deploy roughly USD 5 billion to shareholders in the current fiscal year, including USD 2.5 billion of share repurchases completed in the first quarter and a 15 percent increase to its dividend.MarketBeat That plan follows returns of about USD 5 billion to shareholders in 2024, also including USD 2.5 billion in buybacks in the first quarter of that year and the same 15 percent dividend step-up, reinforcing management’s commitment to combining growth with consistent cash returns.Investing.com

The quarterly dividend has been lifted to USD 0.94 per share, up from the previous USD 0.82 per share, which translates into an annualized dividend of USD 3.76 and a yield of around 0.4 percent at recent share prices.MarketBeat The dividend payout ratio stands near 10.06 percent, leaving ample room for further share repurchases and growth investments while still allowing for potential future dividend increases as earnings expand.MarketBeat

Oncology pivot and strategic deal risk

The planned USD 2.25 billion acquisition of Precision Medicine Group is a key element of McKesson’s oncology and biopharma services strategy, designed to deepen its community-based specialty platform through the U.S. Oncology Network and related assets.Investing.com Analysts and investors view the oncology pivot and higher-margin services as a structural upside driver, especially as the company combines this move with substantial share buybacks and disciplined capital allocation.Seeking Alpha

At the same time, management has pointed to several near-term pressures that could temper operating results in individual segments. These include planned spending in the back half of the year, volatility in the Medical-Surgical business, and ongoing pricing changes tied to the Inflation Reduction Act.Investing.com For shareholders, this means that while the oncology and technology initiatives support long-term growth, there is execution risk around integrating Precision Medicine Group, managing regulatory-driven pricing shifts and delivering the guided margin recovery in Medical-Surgical.

Analyst sentiment and valuation context

According to MarketBeat, McKesson currently carries a consensus analyst rating of “Moderate Buy” with an average price target of USD 973.44, suggesting that the sell-side still sees upside from current levels. The price target implies scope for further appreciation if the company continues to deliver double-digit adjusted operating profit growth in oncology and technology segments while maintaining disciplined capital returns.

Data cited by Investing.com show that McKesson stock recently traded near USD 908, with some analyses describing the shares as undervalued relative to their fundamental profile. Against that backdrop, the combination of approximately 33 percent revenue growth and roughly 41 percent adjusted operating profit growth in Oncology and Multi-Specialty in the first quarter of fiscal 2027 is a key part of the bull case for the stock.Investing.com

Representative product and services focus

McKesson’s oncology strategy is closely linked to its U.S. Oncology Network, which supports community oncology practices with drug distribution, technology tools and care management services.Zacks In first-quarter fiscal 2027, the Oncology and Multispecialty platform delivered the aforementioned 33 percent revenue growth and 41 percent adjusted operating profit growth, showing how patient volume, site-of-care shifts and expanded service offerings are translating into tangible financial results.Zacks

McKesson stock price and market data

Recent market data indicate that McKesson Corporation stock has been trading in the low USD 900 range on the New York Stock Exchange, with a one-day move of around minus 1.45 percent bringing the price to roughly USD 907.99 as of early September 2026.Seeking Alpha With an annualized dividend of USD 3.76 per share and a payout ratio of just over 10 percent, the stock’s current yield remains modest, but the company’s ongoing USD 5 billion capital return plan and strong first-quarter fiscal 2027 segment growth give investors a mix of income, buyback support and operational momentum to weigh.